Why did Dr. Marion Gruber, director of the Office of Vaccines Research and Review and Dr. Philip Krause, deputy director of the office, leave FDA in 2021?
I asked this question here on June 24, 2024 - no answers yet???!!!
Just remembered something
You know how it is sometimes. A thought suddenly pops into your head from nowhere. That’s what happened to me last week. It might have been to do with the dialogue I’ve been having with FDA on the FOIA here:
Now I’m being passed over to the relevant staff at FDA’s Center for Biologics Evaluation and Research (CBER), I remembered two high profile resignations from CBER in 2021.
Below is an article link:
Two senior FDA vaccine leaders step down as agency faces decision on boosters
“Marks said in the email the search for the next director of the Office of Vaccines Research and Review would begin imminently and that he would serve as the acting director.
The letter made no mention about why Gruber and Krause are leaving, but the departures sparked questions about whether it would affect FDA’s work during the pandemic.
“We are confident in the expertise and ability of our staff to continue our critical public health work, including evaluating COVID-19 vaccines,” FDA spo…